Industry News

Santen opens glaucoma research lab in London

Santen announced the creation of its first external research laboratory in Europe. In partnership with the University College London Institute of Ophthalmology, the lab will support the work of young ophthalmology researchers.

“The aim of this research laboratory is to investigate how to prevent and reverse damage that glaucoma causes to the optic nerve and retina and to support some of the brightest minds in the field to find solutions to ophthalmology’s most pressing challenges,” the company said in a press release.

“This is an exciting new development in our strategic partnership with Santen, which has been going from strength to strength since the original memorandum of understanding in 2016,” said Professor Andrew Dick, Director, UCL Institute of Ophthalmology. “I’m grateful to everyone involved for their enthusiasm and dedication to foster the research potential of this partnership; and to UCL Translational Research Office (TRO) for supporting the Institute’s vision to expand our translational research to generate better therapies, diagnostics, and knowledge of eyecare.”

Santen also recently launched the Santen Eyecare Education portal, an interactive medical education platform for ophthalmologists. For more information, please visit

https://santensee.eu.

HAAG-STREIT FOCUSES ON OPHTHALMOLOGY

Haag-Streit reported it will focus solely on ophthalmic surgery, pulling out of its other areas of involvement, including plastic and reconstructive surgery and neurosurgery. HaagStreit products include surgical microscopes, slitlamps, Lenstar biometers, Octopus perimeters, Goldmann tonometers, and surgical simulation solutions. All the products are developed and manufactured in Switzerland, Germany, the UK, and the USA.

LENSAR NOD FROM US FDA

Lensar announced the US FDA accepted its 510(k) submission for its next-generation ALLY™ Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY Adaptive Cataract Treatment System and is the first stage of a planned, two-step commercial release strategy. As part of this strategy, the company plans to submit an additional 510(k) application seeking clearance for the phacoemulsification features within the integrated ALLY system later in 2022. The company believes ALLY will set a new standard of femtosecond laser cataract technology.

Your Professional Dry Eye Assistant

The availability of products and features may vary by country. OCULUS reserves the right to change product specifications and design.

OCULUS Keratograph 5M with JENVIS Pro Dry Eye Report:

All relevant information at a glance!

The new JENVIS Pro Dry Eye Report helps you perform comprehensive screenings, using the measuring results as a basis for diagnosing dry eye syndrome. The workflow is optimized for time saving and patient friendliness. All results are documented and summarized for you and your patient in a neat and easily understandable printout.

www.oculus.de